Venetoclax

Drug Profile

Venetoclax

Alternative Names: ABT 199; GDC-0199; RG 7601; RO 5537382; Venclexta; VENCLYXTO

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Dana-Farber Cancer Institute; Genentech; Nantes University Hospital; Roche
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Multiple myeloma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III Acute myeloid leukaemia; Multiple myeloma
  • Phase II Diffuse large B cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Follicular lymphoma; Mantle-cell lymphoma
  • Phase I Breast cancer; Systemic lupus erythematosus

Most Recent Events

  • 07 Mar 2017 AbbVie plans a phase III trial for Acute myeloid leukaemia (Combination therapy, Treatment-naive) (NCT03069352)
  • 21 Feb 2017 Ohio State University Comprehensive Cancer Center, Celgene and Genentech initiate a phase I trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT02992522)
  • 15 Feb 2017 AbbVie initiates a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (PO, Tablet) (NCT02951117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top